| scholarly article | Q13442814 |
| P50 | author | Michael Roche | Q43480572 |
| Paul A. Ramsland | Q38317548 | ||
| Jasminka Sterjovski | Q39034626 | ||
| Lachlan Gray | Q39034643 | ||
| Anthony L. Cunningham | Q39034658 | ||
| P2093 | author name string | Paul R Gorry | |
| Anne Ellett | |||
| Melissa J Churchill | |||
| Kieran Cashin | |||
| P2860 | cites work | HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor | Q22242268 |
| Identification of a major co-receptor for primary isolates of HIV-1 | Q22251282 | ||
| Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists | Q24619974 | ||
| Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4 | Q27648643 | ||
| Molecular architecture of native HIV-1 gp120 trimers | Q27651385 | ||
| Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility | Q27658989 | ||
| Comparative protein modelling by satisfaction of spatial restraints | Q27860866 | ||
| A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors | Q28118386 | ||
| The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates | Q28282895 | ||
| Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells | Q28288205 | ||
| Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans | Q28345408 | ||
| Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry | Q28475912 | ||
| CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 | Q28646859 | ||
| Contrasting Use of CCR5 Structural Determinants by R5 and R5X4 Variants within a Human Immunodeficiency Virus Type 1 Primary Isolate Quasispecies | Q40132975 | ||
| Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients | Q40953782 | ||
| An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site | Q41530101 | ||
| Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. | Q41655443 | ||
| Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. | Q41857055 | ||
| Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry | Q43694761 | ||
| Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region | Q44106148 | ||
| CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity | Q44601067 | ||
| Envelope glycoprotein determinants of increased entry in a pathogenic simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys | Q45666386 | ||
| HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor | Q48111569 | ||
| Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. | Q54381624 | ||
| HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 | Q29616094 | ||
| Structure of a V3-containing HIV-1 gp120 core | Q29619014 | ||
| Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. | Q29622903 | ||
| Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. | Q30423779 | ||
| Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism. | Q33648601 | ||
| Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes | Q33716586 | ||
| HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry | Q33807529 | ||
| Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates | Q33824289 | ||
| Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers | Q33836042 | ||
| Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity | Q33847458 | ||
| Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate | Q33851094 | ||
| HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells | Q33990552 | ||
| Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. | Q34008699 | ||
| Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection | Q34065091 | ||
| The plasma membrane as a combat zone in the HIV battlefield | Q34078723 | ||
| Single-molecule analysis of human immunodeficiency virus type 1 gp120-receptor interactions in living cells | Q34142829 | ||
| Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. | Q34340428 | ||
| Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele | Q34545588 | ||
| Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. | Q34717126 | ||
| A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection | Q34741807 | ||
| An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes | Q34987062 | ||
| R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies | Q35018129 | ||
| The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. | Q35062297 | ||
| HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism | Q35076868 | ||
| Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions. | Q35835261 | ||
| Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. | Q35890885 | ||
| Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. | Q35985849 | ||
| HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes | Q36573144 | ||
| An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1 | Q36687524 | ||
| The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope | Q36809662 | ||
| Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. | Q36890344 | ||
| Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein | Q36914293 | ||
| Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues | Q37015492 | ||
| Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. | Q37146880 | ||
| Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain | Q37191794 | ||
| Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. | Q37275049 | ||
| Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc | Q37452124 | ||
| Entry inhibitors in the treatment of HIV-1 infection | Q37580460 | ||
| Coreceptors and HIV-1 pathogenesis | Q37824291 | ||
| Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line | Q38324749 | ||
| A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5 | Q38341741 | ||
| Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes | Q38979142 | ||
| Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12. | Q38979760 | ||
| A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5 | Q39000358 | ||
| Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages | Q39021508 | ||
| A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. | Q39022595 | ||
| Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome | Q39031676 | ||
| The emergence and characterization of macrophage-tropic SIV/HIV chimeric viruses (SHIVs) present in CD4+ T cell-depleted rhesus monkeys | Q39092739 | ||
| Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. | Q39317816 | ||
| Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. | Q39351549 | ||
| Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enh | Q39351562 | ||
| Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. | Q39521282 | ||
| Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. | Q39523186 | ||
| Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope. | Q39549145 | ||
| Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. | Q39549670 | ||
| Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo | Q39590956 | ||
| Entry coreceptor use and fusion inhibitor T20 sensitivity of dual-tropic R5X4 HIV-1 in primary macrophage infection. | Q39616140 | ||
| The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor | Q39686562 | ||
| Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: implications for HIV fusion and entry events | Q39755287 | ||
| Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. | Q40113932 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 10699-10709 | |
| P577 | publication date | 2011-08-10 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages | |
| P478 | volume | 85 |
| Q35666270 | A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops |
| Q36827946 | A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations |
| Q36028163 | CCR5 susceptibility to ligand-mediated down-modulation differs between human T lymphocytes and myeloid cells. |
| Q37324797 | Decreased plasticity of coreceptor use by CD4-independent SIV Envs that emerge in vivo |
| Q34537513 | Differences in coreceptor specificity contribute to alternative tropism of HIV-1 subtype C for CD4(+) T-cell subsets, including stem cell memory T-cells |
| Q92990096 | Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage |
| Q26825087 | HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies |
| Q35196509 | HIV-1 target cells in the CNS. |
| Q37102101 | Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. |
| Q37362368 | Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection |
| Q34792976 | Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection. |
| Q36476641 | Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5 |
| Q31153030 | Moderate restriction of macrophage-tropic human immunodeficiency virus type 1 by SAMHD1 in monocyte-derived macrophages |
| Q36281817 | Phenotypic Correlates of HIV-1 Macrophage Tropism |
| Q30372085 | Reliable genotypic tropism tests for the major HIV-1 subtypes |
| Q38973552 | Specific VpU codon changes were significantly associated with gp120 V3 tropic signatures in HIV-1 B-subtype. |
| Q62572413 | Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12 |
| Q36856091 | The HIV-1 env protein: a coat of many colors |
| Q33711710 | The variable loop 3 in the envelope glycoprotein is critical for the atypical coreceptor usage of an HIV-1 strain |
| Q35593158 | Viral determinants of HIV-1 macrophage tropism |
Search more.